理邦儀器(300206.SZ):第一期員工持股計劃鎖定期將於5月4日屆滿
格隆匯4月30日丨理邦儀器(300206.SZ)公佈,公司第一期員工持股計劃鎖定期將於2020年5月4日屆滿。
公司第一期員工持股計劃已於2018年5月3日完成購買,通過二級市場交易的方式累計購買理邦儀器股票約1202.65萬股,成交金額為人民幣9265.78萬元,成交均價為人民幣7.71元,買入股票數量約佔公司總股本的【2.07%】(因實施股份回購計劃,2019年9月27日,公司總股本由5.85億股減少至5.82億股)。此次員工持股計劃所獲公司股票的鎖定期為2019年5月4日起至2020年5月4日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.